Log in to search using one of your social media accounts:


Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.

CONCLUSIONS: The study performed in patients with OAB shows that OXY-TDS provides low incidence of systemic adverse effects, including dry mouth, high persistence, improved adherence rates and high satisfaction of patients after one year of treatment. PMID: 28678009 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research

Related Links:

New Investor Takeda Ventures Joins Syndicate; Proceeds to Fund Lead Clinical Stage Program for the Treatment of Overactive Bladder and Irritable Bowel Syndrome INDIANAPOLIS and LONDON, Nov. 15, 2017 -- (Healthcare Sales &Marketing Network) -- Outpost ... Biopharmaceuticals, Venture Capital, Personnel Outpost Medicine, Irritable Bowel Syndrome, Overactive Bladder
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
This study serves as a basis for future studies seeking to maximize the therapeutic efficacy of sensory pudendal nerve stimulation for the symptoms of OAB. PMID: 29141938 [PubMed - as supplied by publisher]
Source: American Journal of Physiology. Renal Physiology - Category: Physiology Authors: Tags: Am J Physiol Renal Physiol Source Type: research
ConclusionsThis NMA suggests that the efficacy of solifenacin 5 mg/day is at least similar to other common antimuscarinics across the spectrum of OAB symptoms analyzed, and is more effective than tolterodine 4 mg/day in reducing incontinence and UUI episodes. Solifenacin 5 mg/day has a lower risk of dry mouth compared with several agents.
Source: Neurourology and Urodynamics - Category: Urology & Nephrology Authors: Tags: ORIGINAL BASIC SCIENCE ARTICLE Source Type: research
Sacral neuromodulation and alterations in brain activity — discussing discrepanciesSacral neuromodulation and alterations in brain activity — discussing discrepancies, Published online: 14 November 2017; doi:10.1038/nrurol.2017.188NatureArticleSnippet(type=standfirst, markup=Sacral neuromodulation is used to treat refractory overactive bladder (OAB). Recent research has shown that changes in brain activity during sacral neuromodulation relate to its mechanism of action and that these changes vary with device settings. Much remains to be discovered about how sacral neuromodulation influences brain activity, but ...
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research
ConclusionsVaginal prolapse repair with MUS reduced the risk of postoperative SUI in women with preoperative SUI symptoms or occult SUI, but serious adverse events were more frequent. Tweetable abstractLess stress incontinence after vaginal prolapse repair with sling, but more adverse events.
Source: BJOG: An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: Systematic Review Source Type: research
ConclusionsWe did not identify differences in the risk of cardiovascular events or mortality among users of individual antimuscarinic OAB drugs.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
S. Staley, M. Krall and R. Bologna
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Urological Survey Source Type: research
D. Robinson, M. Oelke, V. Khullar, H. Wijkstra, R. Tretter, B. Stow, G. Compion and A. Tubaro
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Urological Survey Source Type: research
Publication date: Available online 11 November 2017 Source:Actas Urológicas Españolas (English Edition) Author(s): A. Alcántara Montero
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Source Type: research
ConclusionTrigone-including onabotulinumtoxinA injection has superior efficacy to trigone-sparing injection without increased complications. The depth of injection does not influence the efficacy or safety of onabotulinumtoxinA.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
More News: Men | Overactive Bladder | Overactive Bladder Syndrome | Oxybutynin | Study | Urology & Nephrology | Women